What is Tango Therapeutics?
Founded in 2017, Tango Therapeutics operates at the intersection of computational biology and drug discovery. The company specializes in identifying synthetic lethal interactions to develop targeted medicines for patients with limited treatment options. Its core mission revolves around the systematic mapping of cancer vulnerabilities, allowing for the creation of highly specific therapeutic agents. As a clinical-stage organization, Tango Therapeutics maintains a robust pipeline that addresses significant unmet needs in oncology, positioning itself as a critical player in the next generation of precision medicine. The company's research-driven approach is designed to accelerate the transition from target identification to clinical validation, ensuring that its therapeutic candidates are optimized for efficacy and safety in complex patient populations.
How much funding has Tango Therapeutics raised?
Tango Therapeutics has raised a total of $455M across 4 funding rounds:
Private Equity
$50M
Other Financing Round
$165M
Stock/Share Issuance
$225M
Private Equity
$15M
Private Equity (2020): $50M with participation from Boxer Capital , LLC, Cormorant Asset Management , LLC, and Casdin Capital , LLC
Other Financing Round (2020): $165M, investors not publicly disclosed
Stock/Share Issuance (2025): $225M supported by Woodline Partners, TCG Crossover, Farallon, and Balyasny Asset Management
Private Equity (2025): $15M, investors not publicly disclosed
Key Investors in Tango Therapeutics
Woodline Partners
San Francisco-based Woodline Partners LP is an investment firm implementing a market neutral equity strategy, focused on the global Healthcare and Technology sectors to generate idiosyncratic alpha.
TCG Crossover
TCG Crossover is a science-driven investment firm focused on advancing disruptive medicines and investing in breakthrough therapies that have the potential to transform healthcare.
Farallon
Farallon is an investment management company that manages discretionary equity capital from institutional investors such as university endowments, foundations, and pension plans.
What's next for Tango Therapeutics?
With the recent influx of capital, Tango Therapeutics is well-positioned to accelerate its clinical development programs and expand its research infrastructure. The strategic allocation of these funds will likely prioritize the advancement of its lead candidates through critical trial phases, while simultaneously bolstering its discovery engine to identify new therapeutic targets. As the company scales, it will focus on strengthening its intellectual property portfolio and fostering strategic partnerships that enhance its ability to bring transformative cancer treatments to market. The current funding environment suggests a clear trajectory toward commercial readiness, with the firm poised to leverage its scientific expertise to address the evolving challenges of the global oncology landscape.
See full Tango Therapeutics company page
